Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsCNTX -0.70%24 Quick Ratio is 8.96 as of Mar. 2026, which is 9% below its 10-year median of 9.86. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Context Therapeutics ranks better than 75.23% on this metric.
Context Therapeutics has a quick ratio of 8.96. It generally indicates good short-term financial strength.
The historical rank and industry rank for Context Therapeutics's Quick Ratio or its related term are showing as below:
CNTX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 9.86 Max: 64.03
Current: 8.96
During the past 7 years, Context Therapeutics's highest Quick Ratio was 64.03. The lowest was 0.01. And the median was 9.86.
CNTX's Quick Ratio is ranked better than 75.23% of 1409
companies
in the Biotechnology industry
Industry Median: 3.59
vs CNTX: 8.96
Context Therapeutics (NAS:CNTX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Context Therapeutics Quick Ratio Related Terms
Context Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Context Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Context Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Context Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Context Therapeutics (CNTX) has a Quick Ratio of 8.96 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Context Therapeutics and its competitors. This is near median its historical median of 9.86. Over the past decade, Context Therapeutics' Quick Ratio has ranged from 0.01 to 64.03. According to the industry distribution chart, Context Therapeutics ranks #349 out of 1409 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Context Therapeutics' Quick Ratio too high?
Context Therapeutics' current Quick Ratio of 8.96 is near median its 10-year median of 9.86. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 64.03. The Biotechnology industry median Quick Ratio is 3.59. Context Therapeutics' value of 8.96 is 149.6% above this industry median. Based on the distribution chart, Context Therapeutics ranks #349 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Quick Ratio compare to INKT and XLO?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #349 out of 1409 companies for Quick Ratio. This places Context Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Context Therapeutics' value of 8.96 is 149.6% above this benchmark. Historically, Context Therapeutics' own Quick Ratio has ranged from 0.01 to 64.03 over the past decade. While the company's 10-year median is 9.86 vs. the industry median of 3.59, Context Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Context Therapeutics's current Quick Ratio of 8.96 is 149.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Context Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Context Therapeutics's current Quick Ratio is 8.96, which is near median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current Quick Ratio of 8.96. The current Quick Ratio is 8.96, which is near median its 10-year median of 9.86 and 149.6% above the Biotechnology industry median of 3.59. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current Quick Ratio is 8.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score
Get the complete analysis for CNTX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTX has been successfully added to your 
